Bioinformatics-Based Identification and Clinical Validation of CHST1 as a Potential Prognostic Gene Associated With EMT in Gastric Cancer.
[BACKGROUND] Gastric cancer (GC) is among the most frequently diagnosed malignancies worldwide.
APA
Qin X, Han Y, et al. (2026). Bioinformatics-Based Identification and Clinical Validation of CHST1 as a Potential Prognostic Gene Associated With EMT in Gastric Cancer.. Frontiers in bioscience (Landmark edition), 31(3), 47627. https://doi.org/10.31083/FBL47627
MLA
Qin X, et al.. "Bioinformatics-Based Identification and Clinical Validation of CHST1 as a Potential Prognostic Gene Associated With EMT in Gastric Cancer.." Frontiers in bioscience (Landmark edition), vol. 31, no. 3, 2026, pp. 47627.
PMID
41914286
Abstract
[BACKGROUND] Gastric cancer (GC) is among the most frequently diagnosed malignancies worldwide. Identifying novel therapeutic targets is of great significance.
[METHODS] GC-related RNA-seq data and matched clinical information were retrieved from the publicly available The Cancer Genome Atlas (TCGA) database. The epithelial-mesenchymal transition (EMT) scores of GC and normal tissues were calculated using the gene set variation analysis (GSVA) package. Weighted gene coexpression network analysis (WGCNA) was applied to identify modules associated with EMT. The survival and clinical relevance of EMT-related core genes were analyzed, and carbohydrate sulfotransferase 1 (CHST1) was selected for further investigation. CHST1 expression was validated in patient-derived GC tissues and GC cell lines. Subsequently, CHST1 expression and mitogen-activated protein kinase (MAPK)/extracellular signal-regulated kinase (ERK) signaling pathway activity were modulated in AGS cells to evaluate their effects on cell proliferation, apoptosis, migration, and EMT. experiments were conducted to elucidate the involvement of CHST1 expression in GC growth.
[RESULTS] The EMT score was markedly higher in GC tissues than in normal tissues. Within the EMT-related module, 7 hub genes (, , , , , , and ) were closely associated with GC prognosis. CHST1 expression was strongly correlated with both the EMT score and T stage. As revealed by survival analysis, patients with high CHST1 expression had shorter overall survival than those with low expression. A marked up-regulation of CHST1 protein expression was observed in clinical GC tissues compared with normal tissues. , CHST1 expression was significantly elevated in GC cell lines. Inhibiting CHST1 expression in AGS and HGC27 cells suppressed cell proliferation, migration, as well as EMT, while simultaneously promoting apoptosis. In AGS cells, CHST1 regulated cell proliferation, apoptosis, migration, and EMT through the MAPK/ERK signaling pathway. , CHST1 significantly promoted GC growth and increased the activity of the MAPK/ERK signaling pathway.
[CONCLUSION] CHST1 is highly expressed in GC and may influence GC progression by regulating the MAPK/ERK signaling pathway.
[METHODS] GC-related RNA-seq data and matched clinical information were retrieved from the publicly available The Cancer Genome Atlas (TCGA) database. The epithelial-mesenchymal transition (EMT) scores of GC and normal tissues were calculated using the gene set variation analysis (GSVA) package. Weighted gene coexpression network analysis (WGCNA) was applied to identify modules associated with EMT. The survival and clinical relevance of EMT-related core genes were analyzed, and carbohydrate sulfotransferase 1 (CHST1) was selected for further investigation. CHST1 expression was validated in patient-derived GC tissues and GC cell lines. Subsequently, CHST1 expression and mitogen-activated protein kinase (MAPK)/extracellular signal-regulated kinase (ERK) signaling pathway activity were modulated in AGS cells to evaluate their effects on cell proliferation, apoptosis, migration, and EMT. experiments were conducted to elucidate the involvement of CHST1 expression in GC growth.
[RESULTS] The EMT score was markedly higher in GC tissues than in normal tissues. Within the EMT-related module, 7 hub genes (, , , , , , and ) were closely associated with GC prognosis. CHST1 expression was strongly correlated with both the EMT score and T stage. As revealed by survival analysis, patients with high CHST1 expression had shorter overall survival than those with low expression. A marked up-regulation of CHST1 protein expression was observed in clinical GC tissues compared with normal tissues. , CHST1 expression was significantly elevated in GC cell lines. Inhibiting CHST1 expression in AGS and HGC27 cells suppressed cell proliferation, migration, as well as EMT, while simultaneously promoting apoptosis. In AGS cells, CHST1 regulated cell proliferation, apoptosis, migration, and EMT through the MAPK/ERK signaling pathway. , CHST1 significantly promoted GC growth and increased the activity of the MAPK/ERK signaling pathway.
[CONCLUSION] CHST1 is highly expressed in GC and may influence GC progression by regulating the MAPK/ERK signaling pathway.
MeSH Terms
Humans; Stomach Neoplasms; Epithelial-Mesenchymal Transition; Prognosis; Cell Line, Tumor; Computational Biology; Gene Expression Regulation, Neoplastic; Sulfotransferases; Cell Proliferation; Animals; Cell Movement; Biomarkers, Tumor; Mice; Female; Gene Regulatory Networks; MAP Kinase Signaling System; Apoptosis; Male
같은 제1저자의 인용 많은 논문 (5)
- Procedural State Anxiety in Pediatric Leukemia Patients Undergoing Bone Marrow Aspiration or Lumbar Puncture: A Cross-Sectional Study Using the Chinese Version of the State Anxiety Scale for Children.
- Differentiating cytology of pancreatic ductal adenocarcinoma and pancreatic neuroendocrine tumors by EUS-FNA through hyperspectral imaging technology combined with artificial intelligence.
- Cuproptosis-related gene PROK1 predicts the diagnosis and prognosis of prostate cancer based on multiple machine learning.
- Potentiating Chemo-Immunotherapy via a Programmable Nanocapsule-Hydrogel Platform for Sequential Tumor Microenvironment Remodeling.
- CD52 signaling via macrophage Siglec-G represents a therapeutic target for cancer immunotherapy.